Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab in Early Alzheimer's Disease (ENGAGE)
NCT02477800Phase 3Terminated
- Sponsor
- Biogen
- Start
- Aug 2015
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Started Aug 2015; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02477800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477800.